NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

Search

Coloplast A-S (Class B)

Closed

727.4 0.86

Overview

Share price change

24h

Current

Min

722

Max

737.6

Key metrics

By Trading Economics

Income

-270M

1B

Sales

73M

7B

P/E

Sector Avg

33.45

73.239

EPS

6.38

Dividend yield

3.03

Profit margin

14.859

Employees

16,628

EBITDA

-42M

2.2B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+11.86% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.03%

3.06%

Next Earnings

6 May 2025

Next Ex Dividend date

12 May 2025

Market Stats

By TradingEconomics

Market Cap

164B

Previous open

726.54

Previous close

727.4

Coloplast A-S (Class B) Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 Mar 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31 Mar 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Mar 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 Mar 2025, 22:28 UTC

Earnings

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke Swings to Loss for 2024 >000002.SZ

31 Mar 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 Mar 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 Mar 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 Mar 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31 Mar 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 Mar 2025, 21:02 UTC

Earnings

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 Mar 2025, 21:01 UTC

Earnings

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Mar 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 Mar 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 Mar 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 Mar 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 Mar 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 Mar 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 Mar 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 Mar 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 Mar 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 Mar 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31 Mar 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Peer Comparison

Price change

Coloplast A-S (Class B) Forecast

Price Target

By TipRanks

11.86% upside

12 Months Forecast

Average 901.38 DKK  11.86%

High 1,056 DKK

Low 720 DKK

Based on 8 Wall Street analysts offering 12 month price targets forColoplast A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

2

Buy

4

Hold

2

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.